---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269538"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:37:05.501733+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end

## Summary
- Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.
- Expects topline data from Phase 3 RINGSIDE (varegacestat) before end of 2025.
- IM-1021 shows objective responses in B-cell lymphoma; initial data in 2026.
- HC74 payload overcomes multi-drug resistance in preclinical models.
- Cash runway into 2027; three preclinical ADCs targeting 2026 IND submissions.

## SEC filing metadata
- accession: 0001193125-25-269538
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/0001193125-25-269538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269538
- JSON: https://secwatch.observer/filing/0001193125-25-269538.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.